Atlas Trials

Celgene

427 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Celgene

RecordFirmDate
A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas (NCT03575351)Celgene2018-10-23
A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL) (NCT03743246)Celgene2018-10-17
A Study of Perpetrator Drug Interactions of Enasidenib in AML Patients (NCT03720366)Celgene2018-10-04
Extension Study to Further Evaluate the Safety, Pharmacodynamics and Pharmacokinetics of Ozanimod and Active Metabolites (NCT03665610)Celgene2018-09-10
An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease (NCT03467958)Celgene2018-08-24
Drug-drug Interaction Study of Ozanimod With Tyramine to Evaluate the Effect on Pressor Response (NCT03694119)Celgene2018-07-24
A Safety Study of CC-92252 in Healthy Adult Subjects and Adult Subjects With Psoriasis (NCT03971825)Celgene2018-07-24
A Study of the First-line Treatment of Patients With Newly Diagnosed Transplant-ineligible Multiple Myeloma in Spain (NCT03602755)Celgene2018-07-19
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells (NCT03435796)Celgene2018-07-19
Drug-drug Interaction Study of Ozanimod With Pseudoephedrine to Evaluate the Effect on Blood Pressure and Heart Rate (NCT03644576)Celgene2018-07-11
A Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease (NCT03464097)Celgene2018-06-27
Drug-drug Interaction Study of Ozanimod With Inhibitor or Inducer of CYP2C8 and/or CYP3A (NCT03624959)Celgene2018-06-20
Trial to Determine the Efficacy and Safety of JCAR017 in Adult Participants With Aggressive B-Cell Non-Hodgkin Lymphoma (NCT03484702)Celgene2018-06-05
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of CC-99677 in Healthy Adult Subjects (NCT03554993)Celgene2018-05-23
A Study to Evaluate Gluten Challenge on Immune Responses in Subjects With Celiac Disease (NCT03521180)Celgene2018-05-11
Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Participants With Relapsed and Refractory Multiple Myeloma (NCT03486067)Celgene2018-04-03
Induction Study #2 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease (NCT03440385)Celgene2018-03-07
Survival in Patients Older Than 60 Years With Newly Diagnosed AML in Spain (NCT03435341)Celgene2018-02-28
Induction Study #1 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease (NCT03440372)Celgene2018-02-27
A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) (NCT03374085)Celgene2018-02-06
A Study to Determine the Efficacy and Safety of Luspatercept in Adults With Non Transfusion Dependent Beta (β)-Thalassemia (NCT03342404)Celgene2018-02-05
Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of CC-90006 in Subjects With Mild to Moderate Plaque-type Psoriasis (NCT03337022)Celgene2018-01-04
Post Marketing Surveillance on Safety Evaluation of POMALYST® (Pomalidomide) Treatment of Multiple Myeloma in Korea (NCT03288974)Celgene2017-12-28
A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies (NCT03310619)Celgene2017-12-20
Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma (NCT03361748)Celgene2017-12-13
A Study to Estimate the Effect Sizes of HRCT Endpoints in Response to Glucocorticoid Induction Therapy in Subjects With Pulmonary Sarcoidosis (NCT03324503)Celgene2017-12-08
A Study to Evaluate the Effect of Multiple Doses of CC-90001 on the Pharmacokinetics of Omeprazole, Midazolam, Warfarin, Rosuvastatin, Metformin, Digoxin, and Nintedanib in Healthy Adult Subjects (NCT03363815)Celgene2017-12-04
A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease (NCT02974322)Celgene2017-12-01
A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion Dependence (NCT03194542)Celgene2017-11-15
Study Evaluating the Effects of Food, Cytochrome P450 Inhibition and Induction on the Pharmacokinetics of CC-122 (NCT03340662)Celgene2017-11-09
A Study to Assess the Pharmacokinetics of Enasidenib (CC-90007) in Subjects With Moderate and Severe Hepatic Impairment. (NCT03290443)Celgene2017-09-21
A Study of Pomalidomide Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain Tumors (NCT03257631)Celgene2017-09-18
Radiolabeled Study of CC-220 in Healthy Male Subjects (NCT03294603)Celgene2017-09-11
← Previous Next →

Track Celgene automatically

Every clearance here is in the API, with alerts when new ones post.